proglumetacin has been researched along with Chronic Disease in 2 studies
proglumetacin : A carboxylic ester obtained by formal condensation of the carboxy group of indometacin with the hydroxy group of 3-[4-(2-hydroxyethyl)piperazin-1-yl]propyl N(2)-benzoyl-N,N-dipropyl-alpha-glutaminate. Used (as its dimaleate salt) to control pain and inflammation associated with musculoskeletal and joint disorders. Following oral administration, it is metabolised to indometacin and proglumide, a drug with antisecretory effects that helps prevent injury to the stomach lining.
Chronic Disease: Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Floris, F | 1 |
| Branco do Amaral, A | 1 |
2 other studies available for proglumetacin and Chronic Disease
| Article | Year |
|---|---|
[Proglumetacin: a flexible and safe anti-inflammatory agent for effective clinical practice].
Topics: Acute Disease; Adolescent; Adult; Aged; Chronic Disease; Dose-Response Relationship, Drug; Drug Eval | 1983 |
Short-term and long-term open evaluation of the efficacy and tolerance of proglumetacin, a new antirheumatic agent.
Topics: Adult; Anti-Inflammatory Agents; Arthritis; Chronic Disease; Female; Humans; Indoleacetic Acids; Mal | 1982 |